The 26S proteasome complex: an attractive target for cancer therapy
about
Role of histone deacetylases in pancreas: Implications for pathogenesis and therapyThe Importance of Ubiquitin E3 Ligases, SCF and APC/C, in Human CancersModulation of apoptosis sensitivity through the interplay with autophagic and proteasomal degradation pathwaysA new prospect in cancer therapy: targeting cancer stem cells to eradicate cancerHomopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome bindingKRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.Adapt, Recycle, and Move on: Proteostasis and Trafficking Mechanisms in MelanomaRegulation of proteasome activity in health and diseaseMulti-target drugs: the trend of drug research and developmentThe ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumorsA phase I trial of bortezomib and interferon-α-2b in metastatic melanoma.Regulating the 20S proteasome ubiquitin-independent degradation pathway.Proteasome functioning in breast cancer: connection with clinical-pathological factorsIdentification of a molecular target of a novel fungal metabolite, pyrrolizilactone, by phenotypic profiling systems.Crystal structure of N-{N-[N-acetyl-(S)-leuc-yl]-(S)-leuc-yl}norleucinal (ALLN), an inhibitor of proteasome.Overexpression of nuclear apoptosis-inducing factor 1 altered the proteomic profile of human gastric cancer cell MKN45 and induced cell cycle arrest at G1/S phase.Loss of urokinase receptor sensitizes cells to DNA damage and delays DNA repairInhibition on Proteasome β1 Subunit Might Contribute to the Anti-Cancer Effects of Fangchinoline in Human Prostate Cancer Cells.Interplay between Structure and Charge as a Key to Allosteric Modulation of Human 20S Proteasome by the Basic Fragment of HIV-1 Tat ProteinA genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity.Carcinogenic Liver Fluke Secretes Extracellular Vesicles That Promote Cholangiocytes to Adopt a Tumorigenic PhenotypeThe Proteasome Inhibitor Bortezomib Affects Chondrosarcoma Cells via the Mitochondria-Caspase Dependent Pathway and Enhances Death Receptor Expression and AutophagyFV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.Proteasome inhibitor MG132 induces NAG-1/GDF15 expression through the p38 MAPK pathway in glioblastoma cellsTargeting ubiquitination for cancer therapies.Inhibitors of the immunoproteasome: current status and future directionsMagnetic fluid hyperthermia enhances cytotoxicity of bortezomib in sensitive and resistant cancer cell linesNegatively charged metal oxide nanoparticles interact with the 20S proteasome and differentially modulate its biologic functional effects.Efficient induction of apoptosis by proteasome inhibitor: bortezomib in the human breast cancer cell line MDA-MB-231.PSMC2 is up-regulated in osteosarcoma and regulates osteosarcoma cell proliferation, apoptosis and migration.A prescription for 'stress'--the role of Hsp90 in genome stability and cellular adaptationTargeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.Apoptosis inducers in chronic lymphocytic leukemia.Label-free Proteomic Analysis of Exosomes Derived from Inducible Hepatitis B Virus-Replicating HepAD38 Cell Line.Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer.Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner.The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib.Acid-labile boronate-bridged dextran-bortezomib conjugate with up-regulated hypoxic tumor suppression.Efficient apoptosis and necrosis induction by proteasome inhibitor: bortezomib in the DLD-1 human colon cancer cell line.Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2/M transition and MCL-1 degradation.
P2860
Q26774080-A4CB1FD8-ABB6-4A29-8488-C0DA585B9E04Q26777305-AAA71394-8214-498C-8B75-0D16C1821F5CQ27016574-4E45D454-38C5-4A5C-925A-C4C1D914B6C7Q27022134-72061323-25F3-4D0A-BF70-43674638CD00Q27677425-F2A720E9-9E30-4D5E-BC3A-1A04EB5080E6Q27853300-8A7BD615-67BE-430D-8FD2-66F8E94E53FFQ28069018-640C6F18-4CB8-42B3-80F9-AD919134B60EQ28392708-77DB96D8-08EE-4F85-B5F2-08F32FF013A9Q28480888-DA7EAA72-C785-4F4F-9974-5FEC91D75080Q34218976-B3DB3758-308D-419D-BAE9-3B661E5E58BDQ34241208-32DCFE8F-B83C-4CE4-AFB4-BCDFD3B6CD4CQ34318192-E52E92ED-9549-4358-A6B5-141E0C964E4FQ34362098-20E04F25-9406-49B4-939D-64617BDECFC4Q35027521-D68061CF-3D3F-4C38-A748-598A0F4E0ED0Q35150882-84FC9D43-BF65-481A-A0E0-7464E5CACD93Q35187533-7F6BD085-F9CD-4880-8A33-11640974F4FCQ35200009-F2E2F59C-592F-424D-8C88-C277FB56B904Q35825885-CACC55AB-EC52-428E-9FEF-66185DD732B3Q35843506-7E424B17-5B98-45AF-839A-D4EA4EF62D99Q35921565-1157D553-070A-41A5-A72D-9A53FFDB1C64Q36208640-371FE470-D61C-4630-8932-2AD0EE960085Q36225532-46560529-5EE0-417A-AA14-A77873061B79Q36293871-1C59BF40-5457-40CE-A968-76FE61CC6470Q36572406-FAC0B4F9-4B80-4375-BAE8-DD884C51E677Q37158445-753D9455-3864-4A51-A842-A44447EEC891Q37292307-98A687B4-1E1B-4986-BE56-7D2D568998E3Q37414942-F68B743B-A540-4AC2-ACF2-EA671FA14D38Q37624470-6481490B-92F2-4930-8F4B-F6DD8B1C90ECQ37631680-9BBA7CEE-9DBF-4769-9F9F-55F710506047Q37702385-EC194ACB-4B53-49F9-838B-DBC129E4E4EFQ38041770-5C3C501B-1EC7-4453-8F8A-1183BD922688Q38059739-55909976-444E-4B50-9E7F-641FFC5EC6A1Q38187815-935F3098-F41F-4CE7-BB2C-4B18E4DAE0ABQ38714573-E3926276-9A32-4B07-8220-E472ADA91F9FQ38717741-2ED63216-18F7-45A7-ADF3-A6995A24DE3EQ38727281-37DD5635-093E-4FB2-8466-75CFE2241908Q38887964-7138D9A9-90D1-4FEC-94B0-B4E43949D6D1Q38897881-C7D4993C-92A1-4015-921A-4357C6A34C09Q38949914-26C088B5-2521-439C-A1FA-80D9A518A68DQ39058933-93B3FD8F-957B-4581-9E34-F4CC65DAD73B
P2860
The 26S proteasome complex: an attractive target for cancer therapy
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
The 26S proteasome complex: an attractive target for cancer therapy
@ast
The 26S proteasome complex: an attractive target for cancer therapy
@en
type
label
The 26S proteasome complex: an attractive target for cancer therapy
@ast
The 26S proteasome complex: an attractive target for cancer therapy
@en
prefLabel
The 26S proteasome complex: an attractive target for cancer therapy
@ast
The 26S proteasome complex: an attractive target for cancer therapy
@en
P2860
P1476
The 26S proteasome complex: an attractive target for cancer therapy
@en
P2093
Sarah Frankland-Searby
Sukesh R Bhaumik
P2860
P356
10.1016/J.BBCAN.2011.10.003
P407
P577
2011-10-18T00:00:00Z